Alexandre Quach1, Jonathan Giovannelli2, Natalie Chérot-Kornobis3, Alina Ciuchete4, Guillaume Clément5, Régis Matran6, Philippe Amouyel7, Jean-Louis Edmé8, Luc Dauchet9. 1. University of Lille, Faculté de Médecine Henri Warembourg, F-59045, Lille Cedex, France; University Hospital of Lille, 2 Avenue Oscar Lambret, F-59000, Lille, France. Electronic address: alexandre.quach85@gmail.com. 2. University of Lille, Faculté de Médecine Henri Warembourg, F-59045, Lille Cedex, France; University Hospital of Lille, 2 Avenue Oscar Lambret, F-59000, Lille, France; Pasteur Institute of Lille, INSERM U1167 RID-AGE, 1 Rue du Professeur Calmette, F-59800, Lille, France. Electronic address: jonathan.giovannelli@gmail.com. 3. University of Lille, Faculté de Médecine Henri Warembourg, F-59045, Lille Cedex, France; University Hospital of Lille, 2 Avenue Oscar Lambret, F-59000, Lille, France. Electronic address: nathalie.cherot@univ-lille2.fr. 4. Pasteur Institute of Lille, INSERM U1167 RID-AGE, 1 Rue du Professeur Calmette, F-59800, Lille, France. Electronic address: alina.ciuchete@gmail.com. 5. University of Lille, Faculté de Médecine Henri Warembourg, F-59045, Lille Cedex, France; Pasteur Institute of Lille, INSERM U1167 RID-AGE, 1 Rue du Professeur Calmette, F-59800, Lille, France. Electronic address: gja.clement@gmail.com. 6. University of Lille, Faculté de Médecine Henri Warembourg, F-59045, Lille Cedex, France; University Hospital of Lille, 2 Avenue Oscar Lambret, F-59000, Lille, France. Electronic address: regis.matran@univ-lille2.fr. 7. University of Lille, Faculté de Médecine Henri Warembourg, F-59045, Lille Cedex, France; University Hospital of Lille, 2 Avenue Oscar Lambret, F-59000, Lille, France; Pasteur Institute of Lille, INSERM U1167 RID-AGE, 1 Rue du Professeur Calmette, F-59800, Lille, France. Electronic address: philippe.amouyel@pasteur-lille.fr. 8. University of Lille, Faculté de Médecine Henri Warembourg, F-59045, Lille Cedex, France; University Hospital of Lille, 2 Avenue Oscar Lambret, F-59000, Lille, France. Electronic address: jledme@univ-lille2.fr. 9. University of Lille, Faculté de Médecine Henri Warembourg, F-59045, Lille Cedex, France; University Hospital of Lille, 2 Avenue Oscar Lambret, F-59000, Lille, France; Pasteur Institute of Lille, INSERM U1167 RID-AGE, 1 Rue du Professeur Calmette, F-59800, Lille, France. Electronic address: luc.dauchet@pasteur-lille.fr.
Abstract
INTRODUCTION: Airway obstruction (AO), mainly due to chronic obstructive pulmonary disease (COPD) in adults, is a major cause of mortality and poor quality of life. However, few data are available for France. This study was designed to calculate the prevalence AO among middle-aged adults in northern France, explore the associated risk factors and evaluate the underdiagnosis. METHODS: The Enquête Littoral Souffle Air Biologie Environnement (ELISABET) was a cross-sectional study of a representative sample of 3276 adults aged from 40 to 64 in two urban areas in northern France (Lille and Dunkirk). Participants filled out a questionnaire and performed spirometry testing, without a reversibility test. RESULTS: The age-standardized estimated prevalence [95% confidence interval] of AO was 16.0% [13.9; 17.9] in Lille and 13.7% [11.7; 15.7] in Dunkirk with the Global initiative for chronic Obstructive Lung Disease (GOLD) definition and 10.8% [9.2; 12.5] and 9.5% [7.9; 11.2] respectively with the lower limit of normal calculated with the Global Lung Initiative (GLI) 2012 equations. AO was associated with age, male gender, tobacco consumption and low body mass index. The underdiagnosis rate was greater than 70%. Previously undiagnosed participants with AO displayed more respiratory symptoms compared with participants without AO and less than participants with previously diagnosed AO. CONCLUSION: The prevalence of AO in northern France ranged from 9.5 to 16.0%, depending on the centre and definition used. The high underdiagnosis rate observed here suggests that greater efforts should be made to identify individuals presenting with the symptoms and/or risk factors associated with AO.
INTRODUCTION:Airway obstruction (AO), mainly due to chronic obstructive pulmonary disease (COPD) in adults, is a major cause of mortality and poor quality of life. However, few data are available for France. This study was designed to calculate the prevalence AO among middle-aged adults in northern France, explore the associated risk factors and evaluate the underdiagnosis. METHODS: The Enquête Littoral Souffle Air Biologie Environnement (ELISABET) was a cross-sectional study of a representative sample of 3276 adults aged from 40 to 64 in two urban areas in northern France (Lille and Dunkirk). Participants filled out a questionnaire and performed spirometry testing, without a reversibility test. RESULTS: The age-standardized estimated prevalence [95% confidence interval] of AO was 16.0% [13.9; 17.9] in Lille and 13.7% [11.7; 15.7] in Dunkirk with the Global initiative for chronic Obstructive Lung Disease (GOLD) definition and 10.8% [9.2; 12.5] and 9.5% [7.9; 11.2] respectively with the lower limit of normal calculated with the Global Lung Initiative (GLI) 2012 equations. AO was associated with age, male gender, tobacco consumption and low body mass index. The underdiagnosis rate was greater than 70%. Previously undiagnosed participants with AO displayed more respiratory symptoms compared with participants without AO and less than participants with previously diagnosed AO. CONCLUSION: The prevalence of AO in northern France ranged from 9.5 to 16.0%, depending on the centre and definition used. The high underdiagnosis rate observed here suggests that greater efforts should be made to identify individuals presenting with the symptoms and/or risk factors associated with AO.
Authors: Elena Andreeva; Marina Pokhaznikova; Anatoly Lebedev; Irina Moiseeva; Olga Kuznetsova; Jean-Marie Degryse Journal: NPJ Prim Care Respir Med Date: 2017-11-14 Impact factor: 2.871
Authors: Esther Román-Conejos; Antonio Palazón-Bru; David Manuel Folgado-de la Rosa; Manuel Sánchez-Molla; María Mercedes Rizo-Baeza; Vicente Francisco Gil-Guillén; Ernesto Cortés-Castell Journal: Sci Rep Date: 2018-09-06 Impact factor: 4.379
Authors: Laura V Klotz; Yves Courty; Michael Lindner; Agnès Petit-Courty; Anja Stowasser; Ina Koch; Martin E Eichhorn; Ioannis Lilis; Alicia Morresi-Hauf; Kristina A M Arendt; Mario Pepe; Ioanna Giopanou; Giannoula Ntaliarda; Sabine J Behrend; Maria Oplopoiou; Valérie Gissot; Serge Guyetant; Sylvain Marchand-Adam; Jürgen Behr; Jan-Christian Kaiser; Rudolf A Hatz; Anne-Sophie Lamort; Georgios T Stathopoulos Journal: Cancer Med Date: 2019-02-25 Impact factor: 4.452